Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
2.090
-0.010 (-0.48%)
At close: Feb 11, 2026, 4:00 PM EST
2.097
+0.007 (0.34%)
After-hours: Feb 11, 2026, 6:32 PM EST
Prelude Therapeutics Market Cap
Prelude Therapeutics has a market cap or net worth of $172.21 million as of February 11, 2026. Its market cap has increased by 100.88% in one year.
Market Cap
172.21M
Enterprise Value
130.16M
1-Year Change
100.88%
Ranking
Category
Stock Price
$2.09
Market Cap Chart
Since the IPO on September 25, 2020, Prelude Therapeutics's market cap has decreased from $806.64M to $172.21M, a decrease of -78.65%. That is a compound annual growth rate of -24.95%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 10, 2026 | 173.03M | -27.59% |
| Dec 31, 2025 | 238.95M | 147.03% |
| Dec 31, 2024 | 96.73M | -70.04% |
| Dec 29, 2023 | 322.85M | 12.32% |
| Dec 30, 2022 | 287.43M | -50.22% |
| Dec 31, 2021 | 577.35M | -80.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 25, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Galectin Therapeutics | 176.01M |
| Molecular Partners AG | 173.30M |
| Sagimet Biosciences | 171.06M |
| Tiziana Life Sciences | 171.02M |
| Editas Medicine | 168.88M |
| Tharimmune | 168.40M |
| Cartesian Therapeutics | 167.98M |
| Tenaya Therapeutics | 164.54M |